Drew R. Jones, Ph.D. - Publications

Affiliations: 
2011 Biochemistry and Molecular Biology University of Arkansas for Medical Sciences, United States 
Area:
Biochemistry, Pharmacology

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Kim SY, Jones DR, Kang JY, Yun CH, Miller GP. Regioselectivity Significantly Impacts Microsomal Glucuronidation Efficiency of R/S-6, 7-, and 8-Hydroxywarfarin. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-25. PMID 29543105 DOI: 10.1080/00498254.2018.1451668  0.96
2014 Jones DR, Wu Z, Chauhan D, Anderson KC, Peng J. A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. Analytical Chemistry. 86: 3667-75. PMID 24611431 DOI: 10.1021/ac500476a  0.96
2013 Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, Cantero G, Cheng D, Jones DR, Wu Z, Li Y, et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 110: 16562-7. PMID 24023061 DOI: 10.1073/pnas.1310249110  0.96
2013 Zhou J, Jones DR, Duong DM, Levey AI, Lah JJ, Peng J. Proteomic analysis of postsynaptic density in Alzheimer's disease. Clinica Chimica Acta; International Journal of Clinical Chemistry. 420: 62-8. PMID 23537733 DOI: 10.1016/j.cca.2013.03.016  0.96
2012 Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metabolism Letters. 6: 157-64. PMID 23331088 DOI: 10.2174/1872312811206030002  0.96
2011 Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. Expert Opinion On Drug Metabolism & Toxicology. 7: 857-74. PMID 21480820 DOI: 10.1517/17425255.2011.576247  0.96
2011 Jones DR, Boysen G, Miller GP. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 879: 1056-62. PMID 21470921 DOI: 10.1016/j.jchromb.2011.03.022  0.96
2010 Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metabolism Letters. 4: 213-9. PMID 20615193  0.96
2010 Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chemical Research in Toxicology. 23: 939-45. PMID 20429590 DOI: 10.1021/tx1000283  0.96
2010 Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metabolism Reviews. 42: 55-61. PMID 19788348 DOI: 10.3109/03602530903209395  0.96
2009 Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chemical Research in Toxicology. 22: 1239-45. PMID 19408964 DOI: 10.1021/tx900031z  0.96
Show low-probability matches.